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Abstract (238 words) 
Background: International recommendations such as the CONSORT and 
International Conference on Harmonisation statements recognize patient adherence 
to prescribed treatment as an important aspect of a treatment’s evaluation, but this 
issue is little assessed. 
Objectives: To evaluate how medication adherence was assessed and reported in 
recently published randomized controlled trials (RCTs). 
Material and Methods: All publications of RCTs assessing pharmacological 
treatments in 6 major chronic diseases published in high-impact-factor journals in 
2003 and 2004 were selected from the Medline database. Two investigators 
analysed how medication adherence was assessed and reported. 
Results: A total of 192 publications were analyzed: 71 in HIV infection, 48 diabetes 
mellitus, 24 rheumatoid arthritis, 23 asthma, 15 hypertension, 7 osteoporosis, and 4 
about 2 of these diseases. The assessment of medication adherence was 
documented in 69 (35.9%) publications, by counting pill intake in half of these. 
Results of adherence were reported in 64 (33.3%) publications. Adherence was 
reported as a quantitative measure: proportion of the treatment prescribed in 27 
articles and as a qualitative measure (adherent patient, yes/no) in 41 (in 4 reports 
both techniques were used). When reported, the median intake of prescribed 
medication was 93%, and the median proportion of “nonadherent” patients was 
6.2%.  
Conclusion: There is important variability in the assessment and reporting of 
medication adherence in published RCTs of pharmacological treatments of selected 
chronic diseases, for a given disease and across diseases. Standardization is 




Medication adherence, which can be defined as taking medication as prescribed or 
as “the extent to which a person’s behavior coincides with medical or health advice” 
(1), is an essential component of a successful health outcome (2, 3). Both clinical 
experience and the literature describe medication adherence as frequently 
inadequate: at least 50% of patients unintentionally omit doses (3-7). Adherence is 
particularly important in chronic diseases: the average adherence with long-term 
medical regimens is estimated at 50% to 65% (8).  
Measurement of medication adherence has been recognized as an important factor 
in medical care and treatment outcome (1, 9). Moreover, the CONSORT statement for 
the reporting of randomized controlled trials recommends showing the flow of 
participants through each stage of a randomized controlled trial and including, in the 
item for follow-up, “the number of participants who completed treatment as allocated 
and the number who did not complete treatment as allocated, by study group” (10). 
Completing treatment includes the notion of taking the medication (i.e., adherence). 
Furthermore, the International Conference on Harmonisation (ICH) guidelines also 
include recommendations to report adherence: “the measures taken to ensure and 
document treatment adherence should be described, e.g., drug accountability, diary 
cards, blood, urine or other body fluid drug level measurements, or medication event 
monitoring” (11). Thus adherence is an important issue in clinical practice in chronic 
diseases and has been recognized by major instances as an important issue for 
randomized controlled trials.  
However, data on whether these recommendations are applied or the 
methodological issues of medication adherence for randomized controlled trials are 
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lacking (12, 13) and even articles describing adherence consider it only in a particular 
context (e.g., definitions of adherence when electronic event-monitoring devices are 
used) (13). 
The complexity of the problem regarding adherence has prevented the development 
of a gold standard method of measurement and the lack of a valid measure of 
nonadherence is itself a major barrier to adherence research.  The first 
methodological difficulty in the issue of medication adherence is assessment. 
Several methods to assess adherence have been proposed; some are based on 
patient recall (patient diary, patient questionnaire 9), and others on more objective 
methods (pill count, blood drug concentrations, or devices such as electronic 
medication-event monitoring 3, 14). To our knowledge, no systematic review of the 
techniques used to measure adherence in clinical trials exists. Another difficulty 
concerns the reporting of adherence. Adherence can be reported either as a 
quantitative measure (i.e., as a proportion of prescribed treatment) or as a qualitative 
measure, i.e., adherent versus nonadherent patients). Finally, another aspect of 
interest concerns the possible effect of nonadherence on the interpretation of trial 
results. For example, for a given sample size, nonadherence, like follow-up loss, 
lowers the study power (15).  
The objectives of this study were to 1) evaluate recent publications of randomized 
controlled trials of treatment of 6 chronic diseases (HIV infection, asthma, 
rheumatoid arthritis, diabetes mellitus, hypertension, and osteoporosis) to determine 
documentation of frequency of medication adherence assessment and 2) determine 
which methods are used to assess and report adherence. The goal is not to be 
exhaustive but, rather, to report a “pilot study” of methodological issues concerning 
adherence. 
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Material and methods 
 
A systematic review of recent randomized controlled trials was performed. 
Publications of 6 major chronic diseases were included: HIV infection, asthma, 
rheumatoid arthritis, diabetes mellitus, hypertension, and osteoporosis. These 
diseases offer a range of different situations and potentially different methodological 
difficulties for assessing adherence, since some are asymptomatic and some require 
polymedication. 
 
1. Search strategy 
We selected publications of all randomized controlled clinical trials assessing self-
administered pharmacological interventions in patients with one of the 6 chronic 
diseases and published over 2 years, between January 1, 2003, and December 31, 
2004, from journals that publish randomized controlled trials: 6 of the highest-impact-
factor general and internal medicine journals and 4 journals with the highest impact 
factor for each concerned specialty (Journal Citation Reports 2003; list of journals is 
in appendix). 
Publications were identified in the Medline database through a search that used the 
following exploded MeSH terms: “asthma OR antiasthmatic agents,” “diabetes 
mellitus,” “rheumatoid arthritis,” “HIV infections OR acquired immunodeficiency 
syndrome,” “hypertension OR antihypertensive agents,” and “osteoporosis,” with a 
limitation to “Randomized Clinical Trials”, “Humans” and English-language articles. 
Publications were included only if the study design was identified as a randomized 
controlled clinical trial, published as a full-text article and assessed a 
pharmacological treatment self-administered by adult patients with one of the 6 
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selected diseases. Results of the article selection process are reported in Figure 1 
(date of article selection process: February 17, 2005). 
 
2. Method for evaluation of publications 
Publications were evaluated based on the full-text articles. The reviewer was not 
blinded to the journal name and the authors, as evidence concerning the effect of 
masking on assessments of trial quality is inconsistent (16, 17).  
A standardised checklist of items was used to collect data from each article.  The 
checklist was developed by the 2 reviewers, LG and FT, in a separate set of articles 
published in 2002; the interpretation of the different scales was discussed to resolve 
any differences in scoring beforehand. (The checklist is available from the authors). 
During the study, one reviewer (LG) evaluated all the articles and the second 
reviewer (FT) independently examined 30 articles chosen randomly; comparison of 
the results obtained for these 30 articles allowed us to calculate inter-rater 
reproducibility. 
Abstracted data included year of publication, funding sources (public or private either 
clearly reported or extrapolated from authors’ affiliations), number of centers 
involved, underlying disease, trial duration, type of treatment assessed (symptom 
modifying versus disease controlling), number of treatments taken simultaneously by 
a patient during the trial and planned in the study design (even if only some of these 
treatments were evaluated), route of administration (oral, topical, subcutaneous, 
inhalation, other).  
The quality of the publications was determined by use of the Jadad scale (18) (score 
0 to 5) and the Delphi list (19, 20) (score 0 to 9). A high score indicates high quality for 
both scales.  
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3. Evaluation of adherence 
Assessment and reporting of adherence 
It was checked whether adherence was described as being assessed in the 
Materials and methods section of each article. If so, the technique or techniques 
used to assess adherence were noted, as well as the moment of evaluation and the 
assessor. When reported, methods used to measure adherence were recorded in 
detail and classified into methods based on the care provider (e.g., pill count, 
physical examination for frequent clinical adverse effects), patients (patients’ self-
report [e.g., written or electronic diary], elicited report [e.g., global or specific 
questioning], or other methods), use of devices (e.g., pill count by electronic 
monitoring 3, 14), biologic elements (e.g., serum levels, urine levels, measurement of 
expected biologic effects) or other methods. 
How adherence was reported and adherence results were noted if available and if 
available results were noted in the different treatment arms.  
Reporting of trial results 
It was checked whether adherence was an outcome measure for the trial, and since 
nonadherence can lower the power of a study (15), it was checked whether 
nonadherence was taken into account in the sample size calculations. 
Elements associated with reporting of adherence in a publication 
As an exploratory analysis, it was checked what elements predicted reporting of 
adherence. The trial or publication characteristics investigated for association with 
reporting of adherence (yes/no) were the disease, journal, journal impact factor, type 
of funding, number of patients, trial duration, number of centers, dates of the trial, 
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whether it was the first publication from a trial, intention-to-treat analysis and 
methodologic quality of the publication. 
 
4. Statistical analysis 
Comparisons between variables involved Fisher’s exact test or the Mann-Whitney 
nonparametric test, as appropriate. Inter-rater reliability between the 2 reviewers 
was assessed by use of the intraclass correlation coefficient (ICC) for continuous 
variables and Kappa statistic for qualitative variables. Nonparametric univariate 
analysis and multivariate stepwise logistic regression were performed between 
reporting of adherence (yes/no) and trial and publication characteristics. All data 





1. Selected publications 
Of the 637 publications identified, 192 were included in the analysis (Figure 1). The 
445 publications excluded were mainly not randomized controlled trials (n=91), not 
assessing a pharmacological therapeutic intervention (n=131), or not about the 
selected diseases (n=72).  
The characteristics of the publications are given in Table 1. Publications described 
mainly trials in HIV infection (n= 71, 37%) and diabetes mellitus (n= 48, 25%). Thirty 
percent of the reports were published in general medical journals. Financial support 
was totally or partially public in 45.8%, private in 43.7% and not reported in 10.4%.  
Patients took a median of 2 medications, with more medications per trial in reports of 
HIV trials; the route of administration was mainly oral (81.8%). The types of 
medications were mainly disease controlling (n= 160 trials, 83.3%) or preventive, 
either of the target disease (n= 7 trials, 3.6%) or of a complication (n= 12 
publications, 6.3%). The median duration of intake of the medications (without a run-
in period) was 48 weeks and the median number of patients participating in the trials 
was 185; these characteristics varied greatly across diseases. 
Items of the CONSORT diagram (11) (flow of participants through each stage of the 
trial) were reported in a flow chart or in the text in 68.3% of the publications. 
The median quality of the articles was high: 3 on the 5-point Jadad scale and 7 on 
the 9-point Delphi list. 
Inter-rater reliability was good: for mention of adherence (kappa=0.93 [95% 
confidence interval (CI)=0.81-1.00]), assessment of adherence (kappa=0.93 [95% 
CI=0.81-1.00]), reporting of adherence (kappa=0.85 [95% CI=0.75-1.00]), the Jadad 
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scale (ICC=0.84 [95% CI=0.69-0.92]) and the Delphi list (ICC=0.85 [95% CI=0.72-
0.93]). 
 
2. Assessment of adherence  
Adherence was described as assessed in 69 (35.9%) publications. However, data 
on methods of assessment was missing in 8 of these (11.6%). 
Table 2 shows the techniques described to assess adherence according to the 
disease. The techniques most frequently described were pill count (n= 34, 49.3% of 
the 69 publications) and patient diary (n= 15, 21.7%), but patient diary was the only 
technique in only 8 of the publications (11.6%). 
Two or more techniques were described in 18 publications (26.1%) and this was not 
more frequent in one disease than in another (p=0.85). Separate results for the 
different techniques were given in only 2 of these publications (11.1%); in fact, in all 
the other cases determining which of the techniques had produced the given results 
was impossible. In most cases (n= 60 publications, 86.7% of 69), all patients were 
evaluated for adherence. Assessments of adherence were described as performed 
at every visit in 44 (63.8%) cases, at specified visits in 11 (15.9%), and this was not 
available in 14 (20.3%). When several drugs were taken, it was not always clear 
which drugs were evaluated for adherence (data unclear in 12 publications, 37.5% of 
32 publications with several drugs and assessment). 
 
3. Reporting of adherence 
Adherence was reported in 64 publications (33.3%). However in 21 articles (10.9%) 
adherence was reported to be assessed but no results were given, and in 26 other 
articles (13.5%) no elements for how adherence was assessed were given, but 
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adherence results were reported (this explains discrepancies between assessment 
and reporting of adherence as seen Table 1). 
Adherence was reported either as a quantitative measure, i.e., as a proportion of 
prescribed treatment (e.g., intake is 67% of the prescribed dosage): in 27 
publications (14.1% of 192), or as a qualitative measure (i.e., adherent versus 
nonadherent patients e.g., 17 patients were nonadherent): in 41 publications (21.4% 
of 192). In 4 publications (2.1%), adherence was reported both as a qualitative and a 
quantitative measure (often as excluded patients in the CONSORT flow-chart and as 
a proportion of medication taken). 
 
Reports defining adherence qualitatively (n= 41; 21.4%) described a cutoff point 
(e.g., a patient was nonadherent if intake was less than 80% of total medication). In 
10 reports (24.4%) several cutoffs were described. In 8 publications, cutoff was 80% 
of medication, and in 6 cutoff was 80% of treatment for 80% of the time. In 7 
publications, a definition of adherence was “patients totally adherent,” and other 
cutoffs used (19 times) varied among studies, ranging from “at least one intake 
(>0%)” to “patients missing just one dose.” In 3 cases (7.3%), the cutoff used was 
unclear. In 23 publications (12.0%), “number of patients excluded for nonadherence” 
was reported, mainly presented in the CONSORT flow chart (18 publications). 
When adherence was reported as a quantitative measure, we could distinguish 
between dose-taking and dose-timing adherence. Dose-taking measures 
(quantitative adherence) assess whether the appropriate number of doses were 
taken and dose-timing measures assess whether the doses were taken within the 
appropriate time interval during the day (e.g., within 25% of the dosing interval). 
Dose-timing adherence was described in only 4 publications (the same 4 
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publications describing electronic monitoring assessment). In only these reports 
were extra doses (not just missed doses) also taken into account for the definition of 
adherence. 
 
4. Adherence results and trial results 
When adherence was reported as a qualitative measure (41 publications), the 
median percentage of “nonadherent” patients was 6.2% (range 0-63.3%) and was 
similar across the treatment arms, when reported. In the 27 publications in which 
adherence was reported as a quantitative measure, the median reported adherence 
was 93% (i.e., intake of 93% of the medication prescribed over the trial duration, 
range 63.5-100%). Adherence was reported separately in the different trial arms in 
41 publications (64.1%), and 22 (31.9%) specified whether adherence was similar in 
the treatment arms.  
 
Adherence was described as an outcome measure in 5 cases (2.6%). Five 
publications (2.6%) documented a run-in period where adherence was evaluated. 
Calculation of the sample size was reported in 125 (65.1%); however, the sample 
size took into account predicted nonadherence in only 2 (1.6% of 125).  
The probability value for the primary outcome measure was available in 164 reports 
(82.8%); in 130 (79.3%) the p value was significant (<0.05) and did not differ 
according to whether adherence was reported or not (p=0.68). 
 
5. Elements associated with reporting of adherence 
The exploratory multivariate analysis revealed that the only elements associated 
with reporting of adherence were the methodologic quality of the publication (Jadad 
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score: p=0.0007; for an increase of one point of Jadad score, OR=1.80 [95% 
CI=1.28-2.52]) and the disease (p=0.04): adherence was more often reported in 
reports of osteoporosis (71.4%), asthma (41.7%) and HIV infection (40.9%) than in 






This study assessed the methodological variability in the field of medication 
adherence in reports of randomized controlled trials of self-administered 
pharmacological interventions for 6 chronic diseases published over 2 years in high-
impact general medical and specialty journals. To our knowledge, this is the first 
description of methods used to assess adherence in a diverse sample of trials in 
different chronic conditions. It provides an unprecedented look into the assessment 
and reporting of adherence in randomized controlled trials, revealing some clear and 
relevant disparities in the definitions of adherence and methods used to report the 
results. 
 
The CONSORT statement and the ICH guidelines both encourage the reporting of 
adherence (10, 11). Despite consistent recommendations for reporting adherence in 
clinical trials, our literature review showed results for adherence were reported in 
only 33% of the publications we assessed, and even less often were assessment 
methods and results given (25%). Furthermore, in the 33% publications, adherence 
was reported as extremely high. Of course, these results give rise to speculation 
regarding the results in the other studies that did not report adherence. Thus, a 
discrepancy exists between what is recommended and what we observed, even in 
recent reports published in high-impact-factor journals with a high methodological 
quality (both according to the Jadad scale and the Delphi list).  
There are some possible explanations for this discrepancy. A simple explanation 
could arise from size constraints for published articles, which force the authors, 
sometimes even at the reviewers’ instigation, to omit some elements from their 
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publications (21). In favour of this explanation, we note that 22 publications (11.5%) 
included some information on either assessment or definition of adherence but no 
results on adherence. Thus, a limitation to our study is that we assessed only 
publications of randomized controlled trials, not the trials themselves.  
 
Another important element that could explain the underreporting of adherence is 
related to the methodological difficulties of how to assess and synthesize and report 
the results of adherence. As indicated by our literature review, to date no consensus 
exists on these aspects. In the evaluated publications, adherence was assessed 
mainly by pill count, but many other techniques were used. Methods of assessment 
were detailed in only 31.8% of publications, despite literature indicating that results 
of adherence depend greatly on the technique of assessment (22-26).  
We also noted great heterogeneity in the definitions of adherence, whether 
proportion of the medication prescribed or adherent patient (yes/no), and in the latter 
case, a large range of cutoffs was described. When adherence was defined as a 
quantitative measure, it was almost always a proportion of the prescribed treatment 
taken. For qualitative cutoffs, the most frequent cutoff was “patient excluded for 
nonadherence,” which is not a reproducible definition of nonadherence and indeed 
can refer to nonadherence to the protocol as well as to the treatment. When a 
numerical cutoff was given for nonadherence, results varied widely among diseases 
studied and for a given disease, which makes comparisons between studies (and 
interpretations of differences in effect size) difficult.  
 
Results of clinical trials can be influenced by patient adherence (27, 28). 
Nonadherence leads to loss of power for a given sample size, which can lead to 
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negative results for trials (15), even if a treatment is efficacious, and this element was 
rarely taken into account in the publications we assessed. Treatment failures that 
are usually assumed to be medication failures may be a result of nonadherence 
rather than lack of efficacy. Thus, adherence should be reported and considered 
when interpreting the results of a trial.  
 
The limitations of our study include the selection of high-impact-factor journals. We 
chose these journals because a high impact factor is a good predictor of higher 
methodological quality of journal articles (29) and because our goal was not to be 
exhaustive but, rather, to raise awareness of methodological issues concerning 
assessment and reporting of adherence. Furthermore, since we found reporting of 
adherence to be associated with methodological quality, we doubt that adherence 
could be reported more in low-impact-factor journals. Another limitation is that we 
chose only 6 diseases; however, these diseases represent a range of difficulties with 
regard to adherence. This comparison allowed us to point out that adherence was 
significantly more often mentioned in reports of osteoporosis, asthma and HIV 
infection, which may reflect the habits and methods of disease trialists.  
To our knowledge, this is the first study comparing the methodology used to 
measure adherence in different diseases. Clearly, there is room for standardization 
across specialties. Finally, we have studied only chronic diseases; but chronic 
diseases are the most relevant for studying adherence, since chronic conditions 
carry with them the issue of medication adherence (8). 
 
In conclusion, this study allowed us to point out the real difficulties in the 
assessment, definition and reporting of medication adherence in randomized 
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controlled trials. Reporting adherence is widely recommended (10, 11); furthermore, to 
allow comparisons of trials by systematic review and meta-analysis, our study 
highlights the need for further research in this domain for standardization of the 
assessment, definition and reporting of medication adherence in trials. In particular, 
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Publications excluded after obtaining the full text 
(n=16) 
- Follow-up or sub-group analyses (n=7) 
- Not self-administered treatment (n=6) 
- Concise communication (n=3) 
Publications excluded on the basis  
of the title and abstract (n=429) 
 
- Not a randomized controlled trials (n=91) 
- Reports not assessing a pharmacological 
therapeutic intervention (n=131) 
- Not self-administered treatment (n=40) 
- Reports not assessing the chosen pathologies 
(n=72) 
- Letter or concise communication (n=18) 
- Reports not assessing adults (n=16) 
- Duplicate publication or follow-up (n=51) 
- Phase II trials (n=10) 
